{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:58Z","timestamp":1793191798921,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Program","doi-asserted-by":"publisher","award":["20YDTPJC00950"],"award-info":[{"award-number":["20YDTPJC00950"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703014"],"award-info":[{"award-number":["81703014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118226","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:36:34Z","timestamp":1760027794000},"page":"118226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis and anti-diabetic evaluation of novel PPAR agonists based on functional group-oriented strategy"],"prefix":"10.1016","volume":"301","author":[{"given":"Sule","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Qie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-1111","authenticated-orcid":false,"given":"Cen","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuou","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118226_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.plipres.2005.12.002","article-title":"From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions","volume":"45","author":"Feige","year":"2006","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejmech.2025.118226_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.biochem.70.1.341","article-title":"Peroxisome proliferator-activated receptor gamma and metabolic disease","volume":"70","author":"Willson","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2025.118226_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118226_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2025.118226_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2025.118226_bib6","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118226_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMp1008233","article-title":"Revisiting the rosiglitazone story--lessons learned","volume":"363","author":"Rosen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118226_bib8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jama.2013.8141","article-title":"Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118226_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","article-title":"Thiazolidinediones and PPARgamma agonists: time for a reassessment","volume":"23","author":"Cariou","year":"2012","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2025.118226_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","article-title":"Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive","volume":"32","author":"Dormandy","year":"2009","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2025.118226_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118226_bib12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.gendis.2018.05.004","article-title":"CMHX008, a PPARgamma partial agonist, enhances insulin sensitivity with minor influences on bone loss","volume":"5","author":"Hou","year":"2018","journal-title":"Genes Dis"},{"key":"10.1016\/j.ejmech.2025.118226_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2022.100221","article-title":"AM-879, a PPARy non-agonist and Ser273 phosphorylation blocker, promotes insulin sensitivity without adverse effects in mice","volume":"17","author":"Terra","year":"2023","journal-title":"Metabol Open"},{"key":"10.1016\/j.ejmech.2025.118226_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103059","article-title":"Selective PPARgamma modulator diosmin improves insulin sensitivity and promotes browning of white fat","volume":"299","author":"Yu","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118226_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1021\/acs.jmedchem.4c02803","article-title":"Identification of novel Organo-Se BTSA-based derivatives as potent, reversible, and selective PPARgamma covalent modulators for antidiabetic drug discovery","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118226_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41392-023-01415-6","article-title":"3-Hydroxybutyrate ameliorates insulin resistance by inhibiting PPARgamma Ser273 phosphorylation in type 2 diabetic mice","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118226_bib17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s40265-024-02088-3","article-title":"Correction: elafibranor: first approval","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118226_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243911","article-title":"The pharmacodynamic and differential gene expression analysis of PPAR alpha\/delta agonist GFT505 in CDAHFD-Induced NASH model","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118226_bib19","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc11-0093","article-title":"Effects of the new dual PPAR alpha\/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism","volume":"34","author":"Cariou","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2025.118226_bib20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/liv.13270","article-title":"The therapeutic landscape of non-alcoholic steatohepatitis","volume":"37","author":"Perazzo","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2025.118226_bib21","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/13543784.2014.954034","article-title":"GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes","volume":"23","author":"Cariou","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.118226_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/metabo15050296","article-title":"Compound 3d attenuates metabolic dysfunction-associated steatohepatitis via peroxisome proliferator-activated receptor pathway activation and inhibition of inflammatory and apoptotic signaling","volume":"15","author":"Zhang","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.ejmech.2025.118226_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115510","article-title":"Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo","volume":"257","author":"Xiang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118226_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113807","article-title":"Discovery of the first-in-class dual PPARdelta\/gamma partial agonist for the treatment of metabolic syndrome","volume":"225","author":"Li","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118226_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/srep34661","article-title":"Discovery of isoquinolinoquinazolinones as a novel class of potent PPARgamma antagonists with anti-adipogenic effects","volume":"6","author":"Jin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118226_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24102019","article-title":"Importance of the proximity and orientation of ligand-linkage to the design of Cinnamate-GW9662 hybrid compounds as covalent PPARgamma agonists","volume":"24","author":"Utsugi","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118226_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2025.118226_bib28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1463-1326.2009.01087.x","article-title":"Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes","volume":"11","author":"Derosa","year":"2009","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2025.118226_bib29","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1172\/JCI98709","article-title":"PPARgamma deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects","volume":"128","author":"Kraakman","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118226_bib30","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1172\/JCI30335","article-title":"Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice","volume":"117","author":"Son","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118226_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejmech.2025.118226_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118226_bib33","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118226_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118226_bib35","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1039\/C9SC05487A","article-title":"Identification and structural insight of an effective PPARgamma modulator with improved therapeutic index for anti-diabetic drug discovery","volume":"11","author":"Jiang","year":"2020","journal-title":"Chem. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:04:32Z","timestamp":1773147872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"alternative-id":["S0223523425009912"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118226","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and anti-diabetic evaluation of novel PPAR agonists based on functional group-oriented strategy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118226"}}